



Understanding Advanced Therapies in Inflammatory Arthritis

Opportunity for Great Benefit with Low Risk

Here are your goals, concerns and related resources based on your selections in the [Arthritis Treatment Risks tool](#). You can use these to discuss with your healthcare team. No data is saved in our system, this is a resource just for you!

Information provided in this tool is to provide a general guidance. It does not replace the individual advice provided by your health care team. Treatments prescribed by your specialist would have been carefully selected to ensure the benefit of the treatment outweighed the risk.

My Goals for Treatment

Additional Notes

[← Return to the Arthritis Treatment Risks tool](#)

1. Konstantinos T et al. Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. *Rheumatology*. 2021; 60 (5): 2223-2230.

2. Xu Z, Xu P, Fan W, et al. Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials. *Exp Ther Med*. 2017;14(4):3491-3500. doi:10.3892/etm.2017.5003

3. Accortt NA et al. Impact of Sustained Remission on the Risk of Serious Infection in patients with Rheumatoid Arthritis. 2018. *Arthritis Care & Research*. 70(5):679-684. DOI 10.1002/acr.23426

4. Youssef J, Novosad SA, Winthrop KL. Infection Risk and Safety of Corticosteroid Use. *Rheum Dis Clin North Am*. 2016;42(1):157-x.
doi:10.1016/j.rdc.2015.08.004

5. Kavanaugh A, Wells AF. Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. *Rheumatology (Oxford)*. 2014;53(10):1742-1751. doi:10.1093/rheumatology/keu135

6. Aysin K et al. Evaluation of influenza and pneumococcal vaccination rates in patients with rheumatoid arthritis and spondyloarthritis, and the awareness of rheumatologists about vaccination. *Annals of the Rheumatic Diseases*. 2020; 79: 1860-1861.

7. Morinobu A. JAK Inhibitors for the treatment of rheumatoid arthritis. 2020. *Immunological Medicine*. 148-155. <https://doi.org/10.1080/25785826.2020.1770948>
8. Strangfeld A, Redeker I, Kekow J, et al. OP0238: Risk of Herpes Zoster in Patients with Rheumatoid Arthritis under Biological, Targeted synthetic, and Conventional Synthetic DMARD Treatment. *Annals of the Rheumatic Diseases*. 2020;79:150-151
9. Genovese MC et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. 2020. *The Lancet Rheumatology*. 2(6): E347-E357. DOI:[https://doi.org/10.1016/S2665-9913\(20\)30032-1](https://doi.org/10.1016/S2665-9913(20)30032-1)
10. Cohen SB, et al. Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift). *RMD Open*. 2021;7:e001673. doi:10.1136/rmdopen-2021-001673.
11. Conahan PG et al. Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program. *Drug Safety* (2021) 44:515-530. <https://doi.org/10.1007/s40264-020-01036-w>
12. Uhlig, T et al. The burden of disease in Rheumatoid Arthritis. *Pharmacoeconomics*. 2014;32: 841-851.
13. Mease PJ et al. Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis or Axial Spondyloarthritis: Data from Two Corrona Registries. *Rheumatol Ther*. 2019;6L529-542.
14. Ackerman I et al. Counting the cost part 1. Healthcare costs: the current and future burden of arthritis. University of Melborne. *Arthritis Australia*. 2016.
15. Fabiola Atzeni, Valeria Nucera, James Galloway, Szekanecz Zoltán & Mike Nurmohamed (2020) Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review, *Expert Opinion on Biological Therapy*, 20:5, 517-524, doi:10.1080/14712598.2020.1704727
16. Ytterberg, S. Cardiovascular and cancer risk with Tofacitinib in Rheumatoid Arthritis. *The New England Journal of Medicine*. 2022;386:316-26. DOI: 10.1056/NEJMoa2109927.
17. Lee, J.L., Sinnathurai, P., Buchbinder, R. et al. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study. *Arthritis Res Ther* 20, 171 (2018). <https://doi.org/10.1186/s13075-018-1669-x>
18. Lee S, Park YJ, Lee JY. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis. *J Korean Med Sci*. 2019;34(42):e278. Published 2019 Nov 4. doi:10.3346/jkms.2019.34.e278
19. Atzeni F, Grillo E, Masala IF, Sarzi-Puttini P, Jones GT. Do Anti-TNF Blockers Increase the Risk of Lung Involvement in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? A Systematic Review. *Isr Med Assoc J*. 2016;18(3-4):154-155.
20. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. *Arthritis Rheum*. 2007;56(5):1433-1439. doi:10.1002/art.22579
21. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. *Ann Rheum Dis*. 2005;64(10):1414-1420. doi:10.1136/ard.2004.033241
22. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. *Ann Rheum Dis*. 2011;70(11):1895-1904. doi:10.1136/ard.2010.149419
23. Dreyer L, Mellemkjær L, Andersen AR, et al. Incidences of overall and site specific cancers in TNF α inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry. *Ann Rheum Dis*. 2013;72(1):79-82. doi:10.1136/annrheumdis-2012-201969
24. Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. *Ann Rheum Dis*. 2009;68(5):648-653. doi:10.1136/ard.2007.085852
25. Mercer LK, Galloway JB, Lunt M, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. *Ann Rheum Dis*. 2017;76(3):497-503. doi:10.1136/annrheumdis-2016-209389
26. Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. *Ann Rheum Dis*. 2010;69(2):400-408. doi:10.1136/ard.2009.117762
27. Hellgren K et al. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs - a Swedish cohort study of risks by time, drug and lymphoma subtype. *Rheumatology (Oxford)*. 2021. 60(2):809-819. doi:10.1093/rheumatology/keaa330.
28. Singh, N, Li, C. Impact of rheumatoid and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence. *Cur Opin Rheumatol*. 2021. 33(3):292-299. doi:10.1097/BOR.00000000000000796.
29. Findeisen K et al. Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician. *Biologics*. 2021. 15:343-352. doi: 10.2147/BTT.S252575
30. Hellgren K, Dreyer L, Arkema EV, et al. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. *Ann Rheum Dis*. 2017;76(1):105-111. doi:10.1136/annrheumdis-2016-209270
31. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. *Ann Rheum Dis*. 2011;70(11):1895-1904. doi:10.1136/ard.2010.149419
32. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. *Pharmacoepidemiol Drug Saf*. 2011;20(2):119-130. doi:10.1002/pds.2046
33. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. *Arthritis Rheum*. 2007;56(9):2886-2895. doi:10.1002/art.22864
34. Amari W, Zeringue AL, McDonald JR, Caplan L, Eisen SA, Ranganathan P. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. *Rheumatology (Oxford)*. 2011;50(8):1431-1439. doi:10.1093/rheumatology/ker113
35. Leggett S, Bosworth A, Hoffstetter C, et al. THU0602 Worker productivity loss remains a major issue for patients with inflammatory arthritis and osteoarthritis: results from the international eular-pro worker productivity study. *Ann Rheum Dis*. 2017;76:433.
36. Claudepierre P, Van den Bosch F, Sarzi-Puttini P, Vastesaeger N, Govoni M, Kachroo S. Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort. *Int J Rheum Dis*. 2019;22(6):995-1001. doi:10.1111/1756-185X.13526
37. Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. *Cochrane Database Syst Rev*. 2015;(4):CD005468. Published 2015 Apr 18. doi:10.1002/14651858.CD005468.pub2

38. Molnar C, Scherer A, Baraliakos X, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. *Ann Rheum Dis.* 2018;77(1):63-69. doi:10.1136/annrheumdis-2017-211544
39. Liu D et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy Asthma Clin Immunol.* 2013; 9(1): 30. doi: 10.1186/1710-1492-9-30
40. Patsalos O, Dalton B, Leppanen J, Ibrahim MAA, Himmerich H. Impact of TNF- α Inhibitors on Body Weight and BMI: A Systematic Review and Meta-Analysis. *Front Pharmacol.* 2020;11:481. Published 2020 Apr 15. doi:10.3389/fphar.2020.00481
41. Shams S, et al. The therapeutic landscape of rheumatoid arthritis: Current state and future directions. *Front. Pharmacol.* 2021.
42. Charlton A, Hazlewood G. Rheumatoid Arthritis. Choices during Pregnancy and Breastfeeding. Compendium of Therapeutic Choices (e-Therapeutics). Last revised: April 14, 2021.
43. Labelling update regarding the use of non-steroidal anti-inflammatory drugs (NSAIDs) beyond 20 weeks of pregnancy and risk of kidney damage to unborn babies. June 8, 2021. Safety Advisory. Health Canada.
44. Mariette X, et al. *Ann Rheum Dis.* 2018 Feb;77(2):228-233.
45. Xeljanz Monograph. Special Populations: Pregnant Women and Nursing Women. (Last revised: Dec. 9, 2021).
46. Rinvoq Monograph. Special Populations: Pregnant Women and Nursing Women. (Last revised: October 5, 2021)
47. Olumiant Monograph. Special Populations: Pregnant Women and Nursing Women. (Last revised: April 9, 2020)
48. Wwww2.gov.bc.ca. 2021. Biosimilars Initiative for Patients - Province of British Columbia. [online] Available at: <https://www2.gov.bc.ca/gov/content/health/health-drug-coverage/pharmacare-for-bc-residents/what-we-cover/drug-coverage/biosimilars-initiative-patients>